You are viewing: India Humanized Mouse and Rat Model Market analysis

The India Humanized Mouse and Rat Model Market was valued at $3.6 Million in 2025 and projected to reach to $5.7 Million by 2030, representing a compound annual growth rate of 9.8%. India's humanized mouse and rat model market is poised for substantial expansion, driven by the country's emerging position as a global pharmaceutical hub and increasing biotech innovation.

India Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Humanized Mouse and Rat Model Market Trends and Insights

  • India's pharmaceutical and biotechnology sectors are increasingly adopting humanized animal models for preclinical drug development and disease research, driven by rising R&D investments and regulatory emphasis on animal model validation.
  • The market in India reflects growing demand from contract research organizations (CROs) and academic institutions seeking advanced in vivo testing platforms. India's position in the Asia Pacific region is strengthened by cost-competitive research capabilities and expanding biotech hubs in cities like Bangalore and Hyderabad.
  • India's humanized model market benefits from collaborations with global pharmaceutical companies outsourcing preclinical studies.
  • The 9.8% compound annual growth rate through 2030 underscores India's emergence as a key player in translational medicine and drug discovery infrastructure within the region..

Key Market Statistics

  • CAGR (2025-2030) 9.8% CAGR
  • Market Size, 2025 ~USD 3.6 Million
  • Forecast, 2030 ~USD 5.7 Million
  • Country India

India Humanized Mouse and Rat Model Market Overview

Market Valuation Growth :

India's humanized mouse and rat model market is valued at USD 3.6 million in 2025, with a strong CAGR of 9.8%, outpacing the global growth rate of 8.2%.

Pharmaceutical R&D Expansion :

Indian pharmaceutical and biotechnology companies are significantly increasing R&D investments, driving demand for humanized animal models in preclinical drug development and efficacy testing.

Regulatory Compliance Driver :

Stringent regulatory requirements from Indian drug authorities and international standards are mandating the use of validated animal models, boosting market adoption across research institutions.

Disease Research Focus :

Growing emphasis on studying complex diseases including cancer, diabetes, and infectious diseases in India is accelerating the adoption of humanized models for translational research.

India Humanized Mouse and Rat Model Market Dynamics

  • The projected growth from USD 3.6 million in 2025 to USD 5.7 million by 2030 reflects rising investments in preclinical research infrastructure and the adoption of advanced animal models by domestic and multinational pharmaceutical companies. The market will be further supported by India's skilled scientific workforce, cost-effective research capabilities, and regulatory push for rigorous drug validation.
  • Collaborations between academic institutions, contract research organizations (CROs), and pharmaceutical firms will accelerate market penetration, positioning India as a key hub for humanized model-based drug development in the Asia-Pacific region..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • India's humanized mouse and rat model market is valued at USD 3.6 million in 2025 and expected to reach USD 5.7 million by 2030, growing at a 9.8% CAGR.
    • India's cost-competitive research infrastructure and expanding biotech ecosystem position the country as an attractive hub for preclinical outsourcing within Asia Pacific.
    • India's pharmaceutical and CRO sectors are driving adoption of humanized models for oncology, immunology, and infectious disease research applications.
    • India's regulatory environment and academic-industry collaborations are accelerating investment in advanced animal model technologies and facilities.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    India Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC AND RESEARCH INSTITUTES0.570.590.630.670.720.770.820.876.7
    CROS & CDMOS1.021.11.221.361.511.671.842.0310.8
    PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES2.242.372.582.833.13.383.6849.2
    TOTAL3.834.054.424.875.335.816.346.919.3

    Target Audience

    • Pharmaceutical Companies : Indian and multinational pharma firms need market intelligence to optimize preclinical development strategies, allocate R&D budgets, and accelerate drug discovery timelines using humanized models.
    • Contract Research Organizations (CROs) : CROs operating in India require detailed market data to expand service offerings, identify client segments, and position humanized model capabilities as competitive differentiators.
    • Biotech & Life Sciences Companies : Emerging biotech startups and established life sciences firms need market insights to validate business models, secure funding, and plan market entry strategies in India's growing sector.
    • Academic & Research Institutions : Universities and government research centers require market analysis to justify funding requests, establish collaborations with industry, and align research programs with market demands.
    • Investors & Private Equity : Investment firms and venture capitalists need comprehensive market data to evaluate investment opportunities, assess growth potential, and identify promising companies in India's humanized model ecosystem.

    Key Companies in the India Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Market Size & Growth Trajectory : Access detailed valuation data showing India's market at USD 3.6M (2025) expanding to USD 5.7M (2030) at 9.8% CAGR, enabling accurate investment and expansion planning.
    • Competitive Landscape Analysis : Understand key players, market consolidation trends, and competitive positioning specific to India's humanized model sector to identify partnership and acquisition opportunities.
    • Regulatory & Compliance Insights : Gain clarity on Indian regulatory requirements, approval pathways, and compliance standards driving market adoption among pharmaceutical and biotech organizations.
    • End-User Demand Segmentation : Identify high-growth segments including pharmaceutical companies, CROs, academic institutions, and government research centers to target sales and marketing efforts effectively.
    • Strategic Growth Opportunities : Discover emerging applications in disease research, technology partnerships, and geographic expansion strategies tailored to India's unique market dynamics and growth drivers.

    Frequently asked questions

    What is the current market size of humanized mouse and rat models in India?

    India's humanized mouse and rat model market was valued at USD 3.6 million in 2025 and is projected to grow to USD 5.7 million by 2030.

    What is the expected growth rate for India's humanized model market?

    India's market is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2030.

    Why is India becoming a hub for humanized animal model research?

    India offers cost-competitive research capabilities, expanding biotech infrastructure in major cities, and strong academic-industry partnerships that attract global pharmaceutical companies for preclinical outsourcing.

    Which sectors in India are driving demand for humanized models?

    India's pharmaceutical companies, contract research organizations (CROs), and academic institutions are primary drivers, particularly for oncology, immunology, and infectious disease research.

    How does India's market compare to the global humanized model market?

    India's 9.8% CAGR exceeds the global average of 8.2%, reflecting faster adoption and investment in preclinical research infrastructure within the Asia Pacific region.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status